Xeris Biopharma Holdings Q2 2024 GAAP EPS $(0.10) Beats $(0.11) Estimate, Sales $46.512M Beat $45.811M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma Holdings (NASDAQ:XERS) reported Q2 2024 GAAP EPS of $(0.10), beating the $(0.11) estimate. Sales were $46.512M, surpassing the $45.811M estimate and marking a 26.07% increase from the same period last year.
August 08, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma Holdings reported better-than-expected Q2 2024 results with EPS of $(0.10) beating the $(0.11) estimate and sales of $46.512M surpassing the $45.811M estimate. Sales increased by 26.07% YoY.
The better-than-expected EPS and sales figures, along with a significant YoY sales increase, are likely to positively impact XERS stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100